Publication | Closed Access

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

Androgen ReceptorNovel Inhibitor DarolutamideUrologyGenitourinary CancerMedicinePharmacologyEnzalutamide-resistant Prostate CancerPharmacotherapyAnti-cancer AgentProstatic DiseaseOncologyDrug Discovery